Follow-On Biologics Pathway Unlikely Without Confirmed FDA Commissioner
• By The Pink Sheet
FDA is unlikely to proceed with developing a follow-on biologics pathway until a permanent commissioner is confirmed, a Senate Health Committee staffer said at a Food & Drug Law Institute conference in Washington, D.C., Nov. 16
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
